Oncimmune Holdings, a London-listed immunodiagnostics developer, has announced significant leadership changes. Martin Gouldstone will be joining the company as the new Chief Executive Officer, effective from August 1. At the same time, Matthew Hall, the current Chief Financial Officer, will step down.
Gouldstone brings with him over 25 years of valuable experience in the life-science sector. Presently, he serves as the global senior vice president at Owkin Inc., an AI biotech company. His extensive knowledge and expertise are expected to greatly contribute to the growth and development of Oncimmune Holdings.
To support the new CEO, Oncimmune has appointed Martin Hudson to the newly created position of Finance Director. Hudson, who has more than 19 years of international experience in both large multinational corporations and smaller entrepreneurial environments, will be joining Oncimmune on September 4. He will work closely with Gouldstone and transition from his predecessor, Matthew Hall, over the following months.
Hudson has a successful track record working with renowned organizations such as the McLaren Group and Williams Advanced Engineering. His diverse background and insights are poised to propel Oncimmune towards further achievements.
At present, shares in Oncimmune Holdings are valued at 16 pence as of 0804 GMT.